C3N-02728
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 54.70773443
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.540
- MYC_TARGETS_V2+0.380
- SPERMATOGENESIS+0.320
- MITOTIC_SPINDLE+0.290
- MYC_TARGETS_V1+0.170
- DNA_REPAIR+0.120
- PANCREAS_BETA_CELLS+0.040
- INTERFERON_ALPHA_RESPONSE-0.010
- KRAS_SIGNALING_DN-0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- NOTCH_SIGNALING-0.580
- ANGIOGENESIS-0.520
- COAGULATION-0.480
- TNFA_SIGNALING_VIA_NFKB-0.460
- HYPOXIA-0.440
- ADIPOGENESIS-0.420
- INFLAMMATORY_RESPONSE-0.410
- P53_PATHWAY-0.400
- APICAL_JUNCTION-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3NWQXPQV | medulloblastoma | — | 0.923 |
| 2 | BS_VVFBW0YH | medulloblastoma | — | 0.918 |
| 3 | C3L-00603 | — | cohortSQ1 | 0.915 |
| 4 | SRR934790 | — | — | 0.915 |
| 5 | SRR1313143 | — | E | 0.914 |
| 6 | BS_QT3NZ2YZ | Embryonal tumors | — | 0.908 |
| 7 | SAMN03290905 | — | — | 0.908 |
| 8 | BS_7FWZ518S | medulloblastoma | — | 0.907 |
| 9 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.907 |
| 10 | BS_W9AT0MR7 | medulloblastoma | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |